Clinical trials: Peripheral Spondyloarthritis
- Condition Peripheral Spondyloarthritis
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Peripheral Spondyloarthritis
Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA)
The objective of this study was to evaluate the efficacy and safety of adalimumab 40 mg administered every other week (eow) subcutaneously (SC) compared to placebo for 12 weeks followed by open label (OL) safety and efficacy…
- Trial name
- NCT01064856
- Testing
- Adalimumab
- Volunteers
- 165 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Spondylitis, Ankylosing
Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment (Study P04465)(COMPLETED)
This is an open-label, controlled sub-study to the parent protocol (P04041, NCT00779935) to examine the expression profile of genes in patients in the active stage of ankylosing spondylitis (AS) compared to the healthy population…
- Trial name
- NCT00778869
- Testing
- Remicade
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Spondylitis, Ankylosing, SpA
Enthesitis With Ultra Sonography Doppler in Spondyloarthropathies Treated With Infliximab (Study P04440)
Subjects will be given 3 infusions of infliximab according to the label at week 0, 2, and 6. Subjects will be followed for a maximum of 18 weeks or until relapse.
- Trial name
- EUSpA (NCT00686894)
- Testing
- PDUS, Infliximab
- Volunteers
- 7 people
- Sponsor
- Merck Sharp & Dohme LLC